FindTrial
Sign In

Efficacy and Safety Evaluation of Chemotherapy Integrated with Targeted Immunotherapy in Patients with Ienvatinib and GEMOX: A Retrospective Analysis of Real-World Evidence

Efficacy and Safety Evaluation of Chemotherapy Integrated with Targeted Immunotherapy in Patients with Intermediate-advanced Intrahepatic Cholangiocarcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500097575
Enrollment
Unknown
Registered
2025-02-20
Start date
2025-03-20
Completion date
Unknown
Last updated
2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intrahepatic cholangiocarcinoma

Interventions

Observation group (Pembrolizumab Combined with Lenvatinib and GEMOX):None

Sponsors

The 5th Medical Center of PLA General Hospital, Beijing, China.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: a) Patients are 18 years old or above. b) Patients have been pathologically diagnosed with cholangiocarcinoma through liver biopsy and have received combined anti - tumor targeted immunotherapy and chemotherapy. c) The Child - Pugh grade is A or B (7). d) The ECOG PS score is 0 - 1. e) There is at least 1 measurable target lesion according to the mRECIST criteria.

Exclusion criteria

Exclusion criteria: a) Having severe comorbidities in any other vital organs. b) Patients having a history of or currently suffering from other malignancies. c) Patients with incomplete medical records.

Design outcomes

Primary

MeasureTime frame
Objective response rate;—

Secondary

MeasureTime frame
Overall survival;Progressive free survival;Tumor response;Adverse reaction;—

Countries

China

Contacts

Public ContactJiamin Cheng

The 5th Medical Center of PLA General Hospital, Beijing, China.

yhlwherever@qq.com+86 10 6528 9338

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026